Epigeneron, Inc. and Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine started a joint research on novel drug target discovery for neurodegenerative diseases.
Epigeneron announced that it has entered into a joint research agreement with Juntendo University School of Medicine (Wado Akamatsu, M.D., Ph.D., Professor, Laboratory for Regenerative Medicine, Center for Genomic and Regenerative Medicine) on drug target discovery to create new therapeutic medicines for neurodegenerative diseases.
Under this collaboration, Akamatsu Laboratory, Juntendo University School of Medicine, and Epigeneron will jointly conduct multi-omics analysis using the locus-specific chromatin Immunoprecipitation (ChIP) for iPS cells. Based on the results of the analysis, Epigeneron and Akamatsu Laboratory aim to identify biomolecules involved in the control of the causative gene of neurodegenerative diseases and create new therapeutic medicine.
About Laboratory of Regenerative Medicine, Center for Genomic and Regenerative Medicine, Juntendo University School of Medicine:
The laboratory of regenerative medicine was opened in 2014 to develop new treatment options for neurogenerative diseases using iPS cell technology. With deep knowledge of neurodevelopment and cell reprogramming technology, such as the iPS cell, the lab members are studying the establishment of cells useful for future regenerative medicine and disease-specific model cells. For more details, please refer to the link below:
Akamatsu Laboratory: https://research-center.juntendo.ac.jp/genome/about/